Ed Reznik retweeted
Happy to report a rigorously controlled, comprehensively characterized mouse model in which cachexia is driven specifically by lung metastases, paired with a genetically identical, non-cachectic control group. Hope cachexia researchers find it useful. biorxiv.org/content/10.648…
3
9
33
2,414
Ed Reznik retweeted
MitImpact 4: a genome-wide resource for the interpretation of coding and non-coding mitochondrial DNA variants
academic.oup.com/nar/advance-ar…
academic.oup.com/nar/advance-ar…
0
1
2
209
Ed Reznik retweeted
Faculty ad is out,
please help spread the word
Come #DreamBig together, without a doubt,
in the best city in the world!
jobs.sciencecareers.org/job/681004/ten…
please help spread the word
Come #DreamBig together, without a doubt,
in the best city in the world!
jobs.sciencecareers.org/job/681004/ten…
🚨We're recruiting! Calling all bold & original thinkers! Folks with imagination, drive & the (rare) ability to find the thin seam where the fantastical and real meet. Come join a thriving science community, in, beyond a shadow of a doubt, the greatest city in the 🌎 @nyknicks
0
43
102
22,054
Ed Reznik retweeted
I'm very happy to share the final version of our paper, “MCT1-dependent mitochondrial lactate import sustains cardiac metabolism,” out in Nature! We show how lactate fuels heart mitochondria and helps protect the heart during stress. nature.com/articles/s4158… @UofUBiochem 1/10
17
68
232
15,697
Ed Reznik retweeted
Incredible study just published in @NatureMedicine by @EdReznik, @CentralParkWMD and colleagues at @MSKCancerCenter on one of the most important and least appreciated topics in oncology, the wasting of muscle and fat that drives weight loss in cancer patients, known as cachexia. Overall, they found a hazard ratio of ~3, meaning cancer patients with cachectic weight loss have TRIPLE the risk of death.
Can counteracting cachexia help keep patients alive? This question is personal for me. In 2015 I lost a dear friend Alan Sonnenfeld to pancreatic cancer with cachexia. In 2018, my @Immuneering $IMRX colleagues and I presented data at AACR supporting the development of a MEK inhibitor with optimized pharmacokinetics to treat cachexia. We subsequently developed a third-generation MEK inhibitor, atebimetinib, designed to both reduce tumor volume and preserve body mass. This week atebimetinib was featured on the cover of Cancer Research, and a few weeks ago we presented data at the AACR Conference on Pancreatic Cancer showing how atebimetinib both reduced tumor volume and preserved body mass in pancreatic cancer patients treated in our Phase 2 study. Atebimetinib is now in Phase 3.
@pfizer also deserves credit for developing ponsegromab for cancer cachexia, but beyond the two of us there is far too little effort in this area. In fact, companies rarely even report weight changes on their clinical trials. Hopefully @EdReznik's important publication will bring more attention to a topic that could make a big difference in keeping cancer patients alive!
Dr. Reznik's Paper:
nature.com/articles/s4159…
Our 2018 Abstract: aacrjournals.org/cancerres/arti…
Our Cancer Research Paper:
aacrjournals.org/cancerres/arti…
Our AACR Conference on Pancreatic Cancer Data:
immuneering.com/wp-content/upl…
Key Ponsegromab Paper: nejm.org/doi/abs/10.105…
Can counteracting cachexia help keep patients alive? This question is personal for me. In 2015 I lost a dear friend Alan Sonnenfeld to pancreatic cancer with cachexia. In 2018, my @Immuneering $IMRX colleagues and I presented data at AACR supporting the development of a MEK inhibitor with optimized pharmacokinetics to treat cachexia. We subsequently developed a third-generation MEK inhibitor, atebimetinib, designed to both reduce tumor volume and preserve body mass. This week atebimetinib was featured on the cover of Cancer Research, and a few weeks ago we presented data at the AACR Conference on Pancreatic Cancer showing how atebimetinib both reduced tumor volume and preserved body mass in pancreatic cancer patients treated in our Phase 2 study. Atebimetinib is now in Phase 3.
@pfizer also deserves credit for developing ponsegromab for cancer cachexia, but beyond the two of us there is far too little effort in this area. In fact, companies rarely even report weight changes on their clinical trials. Hopefully @EdReznik's important publication will bring more attention to a topic that could make a big difference in keeping cancer patients alive!
Dr. Reznik's Paper:
nature.com/articles/s4159…
Our 2018 Abstract: aacrjournals.org/cancerres/arti…
Our Cancer Research Paper:
aacrjournals.org/cancerres/arti…
Our AACR Conference on Pancreatic Cancer Data:
immuneering.com/wp-content/upl…
Key Ponsegromab Paper: nejm.org/doi/abs/10.105…
🎸@EdReznik is a true 🧬scientist and ☝️this is a really important fundamental topic in cancer.
I am honored to be Ed’s collaborator and I learn so much from his insights and creative ways of evaluating this matter that we must improve.
As a clinician, it has been a long due homework to understand. Now we need to start intervening! Now this paper next ones are informing the first systemic roadmap 🚘
Just pure vibe for excellence 👍 and awesomeness 😎
0
3
12
1,722
Ed Reznik retweeted
Researchers at MSK and their collaborators are gaining new insights into cancer cachexia, a wasting syndrome that affects nearly half of all patients.
Findings in @NatureMedicine could help predict which patients are most at risk and help facilitate timely support and re: bit.ly/4yhYfl3
Findings in @NatureMedicine could help predict which patients are most at risk and help facilitate timely support and re: bit.ly/4yhYfl3
2
6
17
2,983
After many years of effort, deliberation, excitement, angst, joy, and Wednesday afternoon lab lunches, our group's first manuscript on cachexia, led by Venise Jan Castillon, Amy Xie, and really our whole lab nature.com/articles/s4159… @NatureMedicine
9
42
128
15,741
If you're interested in coming with my lab on this journey that brings quantitative and computational biology as close to day-to-day medicine as we can manage, apply for a postdoc here msk.wd108.myworkdayjobs.com/en-US/MSKCC_Ca…
1
2
7
674
Finally, thank you to @CancerGrand and the CANCAN team, especially @MarcusDGon @JanowitzTobias and @EileenWhitePhD who continually open my eyes to new and exciting avenues for inquiry into cachexia and tumor-host biology.
0
1
3
346
Ed Reznik retweeted
Team CANCAN is tackling one of cancer’s least understood complications: cachexia
New findings published today in @NatureMedicine, led by @EdReznik
(@MSKCancerCenter), highlight the potential to predict risk of a cachectic event in the hopes of enabling patients and their clinicians to try and get ahead of this devastating condition.
Read our interview with Ed to learn more about the latest research: bit.ly/4hVzSDC
Team CANCAN is co-led by @MarcusDGon, @JanowitzTobias and @EileenWhitePhD, and is funded by @CR_UK and the @theNCI through Cancer Grand Challenges.
New findings published today in @NatureMedicine, led by @EdReznik
(@MSKCancerCenter), highlight the potential to predict risk of a cachectic event in the hopes of enabling patients and their clinicians to try and get ahead of this devastating condition.
Read our interview with Ed to learn more about the latest research: bit.ly/4hVzSDC
Team CANCAN is co-led by @MarcusDGon, @JanowitzTobias and @EileenWhitePhD, and is funded by @CR_UK and the @theNCI through Cancer Grand Challenges.
0
7
12
2,040